Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Sun, Mingyuan
Qiu, Lugui
Wei, Yongqiang
Jin, Jie
Li, Xin
Liu, Xue
Yin, Shaohong
Qi, Junyuan
机构：
[1] Natl Clin Res Ctr Hematol Disorders, Inst Hematol & Blood Dis Hosp, State Key Lab Expt Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Co, Inst Hematol, State Key Lab Expt Hematol, Tianjin, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Co, Blood Dis Hosp, Tianjin, Peoples R China
[4] Southern Med Univ, Nanfang Hosp, Guangzhou, Peoples R China
[5] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Hangzhou, Zhejiang, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, Dept Hematol, Changsha, Peoples R China
[7] Lunan Pharmaceut Grp Co LTD, Linyi, Shandong, Peoples R China
[8] Chinese Acad Med Sci, Blood Inst, Tianjin, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8038
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
    Wong, Sandy W.
    Bar, Noffar
    Paris, Laura
    Hofmeister, Craig C.
    Hansson, Markus
    Santoro, Armando
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Lund, Johan
    Encinas, Cristina
    Yee, Andrew J.
    Oriol, Albert
    Cerchione, Claudio
    de la Rubia, Javier
    Ferstl, Barbara
    Carlson, Kristina
    Ribas, Paz
    Bermudez, Arancha
    Boss, Isaac W.
    Gaudy, Allison
    Li, Shaoyi
    Hsu, Kevin
    Godwin, Colin D.
    Burgess, Michael R.
    San-Miguel, Jesus
    Costa, Luciano J.
    BLOOD, 2022, 140
  • [32] MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)
    Levy, Moshe
    Bahlis, Nizar
    Raje, Noopur
    Costello, Caitlin
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Tomasson, Michael
    Dube, Harman
    Damore, Michael
    Lon, Hoi Kei
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S439
  • [33] A Phase I, Open-Label Study to Evaluate the Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity of PF-06863135, a B-Cell Maturation Antigen/CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Advanced Multiple Myeloma
    Lesokhin, Alexander M.
    Raje, Noopur
    Gasparetto, Cristina J.
    Walker, Justine
    Krupka, Heike I.
    Joh, Tenshang
    Taylor, Carrie T.
    Jakubowiak, Andrzej
    BLOOD, 2018, 132
  • [34] Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1
    Sebag, Michael
    Raje, Noopur S.
    Bahlis, Nizar J.
    Costello, Caitlin
    Dholaria, Bhagirathbhai
    Solh, Melhem
    Levy, Moshe Y.
    Tomasson, Michael H.
    Dube, Harman
    Damore, Michael A.
    Lon, Hoi Ken
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael P.
    Gasparetto, Cristina
    Dalovisio, Andrew P.
    Lesokhin, Alexander
    BLOOD, 2021, 138
  • [35] Gene therapy with B-cell maturation antigen/CD3 bispecific antibody encoding plasmid DNA for treating multiple myeloma
    Peng, Fengping
    Wang, Yuan
    Zhao, Jiliang
    Liu, Hui
    Liu, Zhaoyun
    Ding, Kai
    Zhang, Hongkai
    Fu, Rong
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 (03) : 417 - 421
  • [36] Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
    Girgis, Suzette
    Xin, Shun
    Lin, Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery Scott
    Smit, Jennifer
    Goldberg, Jenna D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] Health-related quality of life in patients with relapsed/refractory multiple myeloma (RRMM) treated with teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody: Patient-reported outcomes in MajesTEC-1.
    Martin, Thomas G.
    Moreau, Philippe
    Usmani, Saad Zafar
    Garfall, Alfred L.
    Mateos, Maria-Victoria
    San-Miguel, Jesus F.
    Rocafiguera, Albert Oriol
    Nooka, Ajay K.
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Krishnan, Amrita Y.
    Bahlis, Nizar J.
    Popat, Rakesh
    Besemer, Britta
    Martinez, Joaquin
    Delforge, Michel
    Fastenau, John
    Gries, Katharine S.
    van de Donk, Niels W. C. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naive to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study
    Bahlis, Nizar Jacques
    Tomasson, Michael H.
    Mohty, Mohamad
    Niesvizky, Ruben
    Nooka, Ajay K.
    Manier, Salomon
    Maisel, Christopher
    Jethava, Yogesh
    Martinez-Lopez, Joaquin
    Prince, H. Miles
    Arnulf, Bertrand
    Rodriguez Otero, Paula
    Koehne, Guenther
    Touzeau, Cyrille
    Raje, Noopur
    Iida, Shinsuke
    Raab, Marc-Steffen
    Leip, Eric
    Sullivan, Sharon
    Conte, Umberto
    Viqueira, Andrea
    Lesokhin, Alexander M.
    BLOOD, 2022, 140
  • [39] MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)
    Dholaria, Bhagirathbhai
    Bahlis, Nizar
    Raje, Noopur
    Costello, Caitlin
    Solh, Melhem
    Levy, Moshe
    Tomasson, Michael
    Dube, Harman
    Damore, Michael
    Lon, Hoi Kei
    Basu, Cynthia
    Skoura, Athanasia
    Chan, Edward
    Trudel, Suzanne
    Jakubowiak, Andrzej
    Chu, Michael
    Gasparetto, Cristina
    Dalovisio, Andrew
    Sebag, Michael
    Lesokhin, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S17 - S17
  • [40] REGN5458, a BCMA x CD3 Bispecific Monoclonal Antibody, Induces Deep and Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Madduri, Deepu
    Rosko, Ashley
    Brayer, Jason
    Zonder, Jeffrey
    Bensinger, William I.
    Li, Jingjin
    Xu, Linzhi
    Adriaens, Lieve
    Chokshi, Dhruti
    Zhang, Weijiang
    Boyapati, Anita
    Sharma, Manish
    Seebach, Frank
    Sirulnik, L. Andres
    Weinreich, David M.
    Yancopoulos, George D.
    Dhodapkar, Madhav V.
    Lentzsch, Suzanne
    Cooper, Dennis
    Jagannath, Sundar
    BLOOD, 2020, 136
12345